Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

By M. Ziol, A. Handra‐Luca, A. Kettaneh, C. Christidis, F. Mal, F. Kazemi, V. de Lédinghen, P. Marcellin, D. Dhumeaux, J. Trinchet and 1 more. Hepatology, 2005

1,754 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/8daee147d31b8a9dec035ef83442305f1e7534cf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Asociacion Latinoamericana para el Estudio del Higado
2. Laurent Castéra
3. M. Kudo

In Hepatology

1. Asociacion Latinoamericana para el Estudio del Higado
2. M. Kudo
3. Laurent Castéra

Citations in the corpus

• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “The two index studies suggesting the interest of TE in the assessment of liver fibrosis have been conducted in patients with chronic hepatitis C [126,127].”
• Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. (2010, methodology): “Internal validation was performed using the Jack-Knife method (Steyerberg et al. 2001; Ziol et al. 2005).”
• Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. (2008, neutral): “…% AUROC Cut-off value, kPa Sensitivity, % Specificity, % AUROC Cut-off value, kPa Sensitivity, % Specificity, % Sandrin et al, 2003 0.88 0.91 0.99 Ziol et al, 2005 0.79 8.8 56 91 0.91 9.6 86 85 0.97 14.6 86 96 Castera et al, 2005 0.83 7.1 67 89 0.90 9.5 73 91 0.95 12.5 87 91 Foucher et al,…”
• WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. (2015, background): “fibrosis in patients with chronic hepatitis C (Castera et al. 2005; Ziol et al. 2005).”
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007, neutral): “5 19 (14-25) 98 (97-100) 64 (53-75) 97 (95-98) 10 33 (26-39) 97 (95-99) 78 (68-87) 94 (91-96) 15 42 (35-49) 96 (93-98) 84 (76-93) 91 (88-94) 20 49 (42-56) 94 (91-97) 88 (80-95) 88 (85-91) 25 55 (47-62) 93 (90-96) 90 (83-97) 86 (82-89) 30 59 (52-66) 92 (88-95) 91 (85-98) 83 (80-87) 35 63 (56-70) 90 (”